| Hazard Information | Back Directory | [Uses]
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma[1][2][3]. | [in vivo]
Tislelizumab (10 mg/kg; Intraperitoneal injection; Once a week; 4 weeks) has significant antitumor effect in the B16F10 melanoma mouse model[2]. | Animal Model: | B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice[2] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); once a week for 4 weeks. | | Result: | Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition. |
| [storage]
Store at -20°C | [References]
[1] Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. DOI:10.1001/jamaoncol.2021.0366
[2] Hong Y, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021 Mar;11(3):782-792. DOI:10.1002/2211-5463.13102
[3] Zhu K, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol. 2024 Feb 22;15:1355081. DOI:10.3389/fphar.2024.1355081 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|